Integrated, scalable solutions that accelerate drug products from development to commercialisation and beyond: speedsolutions

Published: 6-Oct-2023

PCI’s speedsolutions, a robust consultative service, is purpose-built to offer the speed and flexibility demanded by today’s clients at every phase of the product lifecycle to accelerate drug development and supply

Through these services, PCI provides seamless and expedited solutions at critical moments in a programme’s lifecycle.

Irrespective of when clients enter the PCI world, they are supported with the option of an end-to-end solution both within specific phases of the product lifecycle and throughout their development to commercialisation journey.  

speedsolutionsTM combines both the core services expected of a CDMO with specialist in-house expertise and additional value-added services for which clients may have previously used third-party vendors.

Such services include package design and development, artwork services, clinical supply management, regulatory support and late stage customisation, to name a few.

By offering these additional services, PCI is able to reduce the overall complexity of vendor management for clients. For example, PCI’s highly skilled packaging design and development experts maximise agility and efficiency in operations.

They support design conceptualisation at the early stages, facilitating informed decisions about material selection and driving patient-centric design and user interaction for ease of production.

Expertise in environmental-friendly packaging is also a value add. Rapid prototyping and late-stage customisation capabilities provide streamlined and flexible solutions.

Another competitive differentiator for PCI is our clinical Supply Management and Readiness Team (SMART) service; this is designed to manage the clinical drug supply of small and midsize clients that have limited resources to tackle the complexities of Phase I, II and III clinical trials internally.

SMART members embed themselves into each customer’s operations and manage their entire supply chain, ordering required items, co-ordinating schedules of bills, shipping products around the world and getting drug product to clinical trial sites on time.

The real value of speedsolutions is being a single source for all aspects of a client’s drug product project, eliminating the complexities of working with multiple vendors to bring their novel therapy to market.

Driving innovation through strategic investments PCI continues to invest and increase its capabilities and capacity in high-growth development areas such as sterile drug product development and manufacturing, as well as packaging for patient-centric drug delivery formats.

We have invested in both our manufacturing and packaging facilities to support our clients and deliver a seamless solution at every stage of the drug product lifecycle.

Enhancing our global sterile fill-finish capabilities and capacities, significant investments have been made in new automated vial-filling technology. With an allocated $100 million budget, a high-speed multiproduct sterile vial filling line with integrated twin lyophilisers is being added to our Bedford (NH, US) campus.

This line utilises full isolator technology and can fill batches of up to 200,000 vials at a rate of up to 400 vpm.

This is complemented by strategic investments in gloveless, fully automated robotic sterile-fill-finish capabilities at our San Diego (CA, US) and Melbourne (Australia) facilities to support the aseptic filling of ready-to-use (RTU) components such as vials, syringes and autoinjector cartridges.

Supporting the exponential growth in client need for advanced drug delivery packaging solutions, we have invested more than $100 million in our Philadelphia (PA, US) commercial packaging facility.

Integrated, scalable solutions that accelerate drug products from development to commercialisation and beyond: speedsolutions

This has increased both our capabilities and capacity for the biotech market with advanced drug delivery packaging lines for prefilled syringe assembly, autoinjector and drug-device combination products.

We are also building a second facility in Rockford (IL, US) at a cost of $150 million to expand our biologic packaging capabilities with additional vial, prefilled syringe and autoinjector assembly and packaging technologies.

These strategic investments — across both manufacturing and packaging— allow PCI to provide integrated end-to-end solutions that reduce both supply chain complexity and risk for client partners.

Combining expertise in sterile fill-finish manufacturing with specialist advanced drug delivery biologic packaging, labelling and cold chain distribution provides a valuable end-to-end solution that simplifies supply chains while delivering time and cost efficiencies.

Digital transformation, our digital customer platform PCI’s commitment and investment in digital transformation utilises innovative technology to differentiate what we do. pci | bridge™ complements our project management capabilities by creating efficient and uncomplicated ways of working together.

Our digital platform provides industry leading customer experience and increases productivity with access to real-time supply chain information and digital workflows through

  • easy access to production and distribution status
  • open invoicing and inventory information
  • documentation approvals
  • easy reporting features at the touch of a button.

No matter when clients enter the PCI world of speedsolutions, their unique journey towards commercialisation will be tailored to their specific needs; this allows them to experience the ultimate in solution flexibility and complete customer-centricity with truly integrated solutions from development to commercialisation. 

Relevant companies

You may also like